FeedworthyAI
Back to feed
InvestorBrandNetworkBusiness & Financenews

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer

Monday, March 23, 2026InvestorBrandNetwork (IBN)View original
Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while […]